Night Walker: Restless Legs Syndrome

Do creepy-crawly feelings in your legs have you walking the night away? You may have restless legs syndrome.

From the WebMD Archives


Restless Legs Syndrome: New Treatments Bring Relief

In 2005, the FDA approved Requip (ropinirole) for the treatment of moderate-to-severe restless legs syndrome. Requip is the first FDA-approved medication for RLS. In 2006, Mirapex (pramipexole) was also approved. Neupro (rotigotine) was approved in 2012.

These drugs act like dopamine. They attach to nerves and change the way they "talk" to each other. In clinical trials, these medicines relieved symptoms of restless legs syndrome in about 75% of people. Both drugs also prevented relapses during long-term use.

Many other medicines have been shown to help people with restless legs syndrome. Physicians often use combinations of medicines to get RLS under control.

Dopamine-like Medicines

These medicines act like dopamine, similar to those mentioned above. Dopamine-like medicines in general work the best in reducing restless legs syndrome symptoms. They include:

Nausea is the most common side effect of dopamine-like medicines. Another potential problem: taken frequently, these drugs can actually worsen symptoms of restless legs syndrome. Called "augmentation," this problem is more common with levodopa than with newer medicines.

Other Medicines for Restless Legs Syndrome

Several other kinds of medicines have shown benefit for RLS. They act in different ways to "calm down" nerve activity:

Restless legs syndrome often relapses, even after an effective treatment is started. "What's very interesting and strange about treating [RLS] is it's a constantly changing landscape," says Bell. "What works for you may not work for someone else, and what works for you now may not work for you a year from now."

Walt Kolakowski, 60, understands this well. Over 30 years, he tried multiple treatments for his restless legs syndrome. For Walt, dopamine-like medicines worked -- but caused too many side effects. He experienced the classic symptoms and progression of severe restless legs syndrome. Today, his symptoms are "somewhat controlled" with gabapentin and hydrocodone.

Fortunately, most people with restless legs syndrome do very well, says Buchfuhrer. For many, he says, the new dopamine-like drugs are "a godsend." In his experience, "95% of people can get free of restless legs symptoms 95% of the time" using some combination of treatments. Goodbye night walking, goodbye "creepy-crawlies." After finding a regimen that works, he adds, "they're the happiest patients -- it's my favorite disease to treat."

WebMD Feature Reviewed by Brunilda Nazario, MD on May 20, 2008


SOURCES: News release, FDA. Mark Buchfuhrer, MD, attending staff physician, Downey Regional Medical Center, Downey, Calif. Georgianna Bell, executive director, Restless Legs Syndrome Foundation. James Connor, PhD, professor and vice chairman, Department of Neurosurgery, Penn State University, State College, Pa. Walt Kolakowski, Jackson, Mich. National Institute of Neurological Disease and Stroke, National Institutes of Health web site: "Restless Legs Syndrome Fact Sheet." Ekbom, K. Acta Medica Scandinavica, 1945; vol 158: pp 4-122. Willis, T. LondonPractice of Physick, publisher unknown, 1685. eMedicineHealth: "Restless Legs Syndrome." Earley, C. New England Journal of Medicine, 2003; vol 348: pp 2103-2109. Restless Legs Syndrome Foundation web site message boards. Walters, A. Movement Disorders, 1995; vol 10: pp 634-638. Allen, R. Sleep Medicine, 2003; vol 4: pp 101-110. Ekbom, K. Neurology, 1960; vol 10: pp 868-874. Kavanagh, D. American Journal of Kidney Diseases, 2004; vol 43: pp 763-771. Lopes, L. Diabetes Care, 2005; vol 28: pp 2633-2636. Garcia-Borreguero, D. Neurology, 2003; vol 61: pp S49-S55. Manconi, M. Neurology, 2004; vol 63: pp 1065-1069. Press release, GlaxoSmithKline. Medscape Medical News: "FDA Approvals: Allegra Oral Solution, Noxafil, Mirapex." Comella, C., Neurology, 2002; vol 58: pp S87-S92.

© 2007 WebMD, Inc. All rights reserved.